AGE-RELATED MACULAR DEGENERATION

This early-stage study tests the safety of an experimental drug called RO7669330, given as an eye injection, for people with geographic atrophy (a severe form of dry age-related macular degeneration). The study involves 27 participants and will monitor side effects and eye health…

This early-stage study tests a new drug called Kamuvudine-8 (K8) for people with geographic atrophy, an advanced form of age-related macular degeneration that causes vision loss. About 30 participants will receive eye injections of K8 and be monitored for 26 weeks to check safety…

This study follows 18 people who already received RetinoStat, a gene therapy for wet age-related macular degeneration, to see if it remains safe over time. Researchers track side effects and vision changes. The goal is to understand long-term risks, not to test if the treatment w…

This early-stage study tests a gene therapy called KH631 for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The treatment aims to deliver a protein that blocks abnormal blood vessel growth, potentially reducing the need for frequent eye in…

This early-stage trial tests a gene therapy called KH658 in 9 people with wet age-related macular degeneration (AMD). The treatment delivers a protein that blocks VEGF, the cause of abnormal blood vessel growth, using a single injection into the eye. The goal is to see if it is s…

This study tests whether a pre-filled syringe is as safe as the standard vial when giving an eye injection for wet age-related macular degeneration, diabetic macular edema, or branch retinal vein occlusion. About 120 people will receive the drug ONS-5010 (bevacizumab) either from…

This early-stage study tests a gene therapy called NG101 for wet age-related macular degeneration (wAMD), a leading cause of vision loss. About 20 adults aged 50-89 who need frequent eye injections will receive a one-time treatment under the retina. The goal is to see if it is sa…

This study tests a new treatment called OpRegen, made from human stem cells, for people with advanced dry age-related macular degeneration (geographic atrophy). The cells are injected under the retina to replace damaged support cells. The main goal is to check safety, but researc…

This study evaluates a system called AVIGA that uses eye-tracking to detect central vision problems in people with wet age-related macular degeneration (AMD). Researchers will compare the system's results with standard tests like eye scans and vision charts. The goal is to see if…

This study tests a new, high-resolution 3D eye scanner that can see both the structure and health of cells in the back of the eye. Researchers will scan 50 people with early age-related macular degeneration (AMD) to see if the device can spot early signs of the disease. The goal …

This study follows 400 people with intermediate age-related macular degeneration (iAMD) for about 3 years. Researchers watch how quickly the disease moves to more advanced stages and test if measuring light-sensing cell loss is a useful way to track the disease. No treatment is g…

This study follows 57 people with age-related macular degeneration (AMD) for up to 5 years to see how their eyes adjust to darkness over time. Participants, who completed an earlier study, will have eye exams and dark adaptation tests at least 6 times. The goal is to better under…

This study looks at whether a specific kind of blood vessel that grows under the retina in age-related macular degeneration (AMD) might actually help preserve vision, rather than harm it. Researchers will follow 73 people aged 50 and older with AMD to compare vision and eye struc…

This study is a 5-year extension that follows people who were in the original AREDS or AREDS2 studies. The goal is to observe how age-related macular degeneration (AMD) and cataracts naturally progress over time. Participants get a yearly eye exam and a phone check-in. No new tre…

This study follows 217 adults aged 50 and older with or without early to middle dry age-related macular degeneration (AMD) for up to 5 years. Researchers use a 20-40 minute dark adaptation test to measure how quickly eyes recover in low light. The goal is to see if this test can …

This study tests whether AI-assisted software helps eye doctors diagnose four common eye diseases more accurately and quickly. Ten eye doctors and residents will review eye images with and without AI help. The goal is to see if AI improves diagnosis and saves time.